Skip to main content
SpringerLink
Log in

Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Purpose

There are limited treatment options for progressive atypical pituitary adenomas and carcinomas. Peptide receptor radionuclide therapy that targets somatostatin receptors has recently been proposed as a potential treatment option. The theoretical rationale for efficacy is elegant but evaluation of outcomes in the first patients treated for this indication is required to assess whether further study is warranted.

Methods

We performed a case review of the three pituitary patients we have treated with 177Lutetium DOTATATE in our institution (two atypical adenomas, one carcinoma) and dosimetric analysis of the radiation uptake in one patient.

Results

Treatment was well tolerated. One patient with slowly progressive pituitary carcinoma has stable disease 40 months after completing the planned 4 cycles of treatment. Two patients with rapidly progressive atypical adenomas terminated treatment early due to continued disease progression. Dosimetric evaluation revealed inhomogenous uptake across the tumour (1.3–11.9 Gy with one cycle).

Conclusion

We have found mixed results in our first 3 patients with stable disease achieved only in the patient with the more slowly progressive tumour. As only a limited number of centres offer Peptide receptor radionuclide therapy, a formal study with prospective data collection may be feasible and if carried out should include dosimetric evaluation of absorbed dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Saeger W, Ludecke DK, Buchfelder M et al (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156:203–216

    Article  CAS  PubMed  Google Scholar 

  2. Zada G, Woodmansee WW, Ramkissoon S et al (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114:336–344

    Article  PubMed  Google Scholar 

  3. Kaltsas GA, Nomikos P, Kontogeorgos G et al (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90:3089–3099

    Article  CAS  PubMed  Google Scholar 

  4. Lopes MB, Scheithauer BW, Schiff D (2005) Pituitary carcinoma: diagnosis and treatment. Endocrine 28:115–121

    Article  CAS  PubMed  Google Scholar 

  5. Ortiz LD, Syro LV, Scheithauer BW et al (2012) Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo) 67(Suppl 1):119–123

    Article  Google Scholar 

  6. Kaltsas GA, Mukherjee JJ, Plowman PN et al (1998) The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 83:4233–4238

    Article  CAS  PubMed  Google Scholar 

  7. Colao A, Grasso LF, Pivonello R et al (2011) Therapy of aggressive pituitary tumors. Expert Opin Pharmacother 12:1561–1570

    Article  CAS  PubMed  Google Scholar 

  8. Laws ER Jr, Morris AM, Maartens N (2003) Gliadel for pituitary adenomas and craniopharyngiomas. Neurosurgery 53:255–269 discussion 259–260

    Article  PubMed  Google Scholar 

  9. Ortiz LD, Syro LV, Scheithauer BW et al (2012) Anti-VEGF therapy in pituitary carcinoma. Pituitary 15:445–449

    Article  PubMed  Google Scholar 

  10. Ramirez C, Cheng S, Vargas G et al (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97:1745–1751

    Article  CAS  PubMed  Google Scholar 

  11. Acosta-Gomez MJ, Muros MA, Llamas-Elvira JM et al (2005) The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours. Br J Radiol 78:110–115

    Article  CAS  PubMed  Google Scholar 

  12. Jaquet P, Ouafik L, Saveanu A et al (1999) Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84:3268–3276

    CAS  PubMed  Google Scholar 

  13. Taboada GF, Luque RM, Bastos W et al (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65–74

    Article  CAS  PubMed  Google Scholar 

  14. Saveanu A, Gunz G, Guillen S et al (2006) Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 83:258–263

    Article  CAS  PubMed  Google Scholar 

  15. Hofland LJ, Lamberts SW, Feelders RA (2010) Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells. Neuroendocrinology 92(Suppl 1):11–16

    Article  CAS  PubMed  Google Scholar 

  16. Hofland LJ, Feelders RA, de Herder WW et al (2010) Pituitary tumours: the sst/D2 receptors as molecular targets. Mol Cell Endocrinol 326:89–98

    Article  CAS  PubMed  Google Scholar 

  17. Fusco A, Giampietro A, Bianchi A et al (2012) Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 15:571–578

    Article  CAS  PubMed  Google Scholar 

  18. Rahmim A, Zaidi H (2008) PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 29:193–207

    Article  PubMed  Google Scholar 

  19. Kuyumcu S, Ozkan ZG, Sanli Y et al (2013) Physiological and tumoral uptake of (68)Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann Nucl Med 27:538–545

    Article  CAS  PubMed  Google Scholar 

  20. Kunikowska J, Krolicki L, Pawlak D et al (2012) Semiquantitative analysis and characterization of physiological biodistribution of (68)Ga-DOTA-TATE PET/CT. Clin Nucl Med 37:1052–1057

    Article  PubMed  Google Scholar 

  21. Boy C, Heusner TA, Poeppel TD et al (2011) 68 Ga-DOTATOC PET/CT and somatostatin receptor (sst1–sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 38:1224–1236

    Article  CAS  PubMed  Google Scholar 

  22. Shastry M, Kayani I, Wild D et al (2010) Distribution pattern of 68 Ga-DOTATATE in disease-free patients. Nucl Med Commun 31:1025–1032

    PubMed  Google Scholar 

  23. Veit JA, Boehm B, Luster M et al (2013) Detection of paranasal ectopic adrenocorticotropic hormone-secreting pituitary adenoma by Ga-68-DOTANOC positron-emission tomography-computed tomography. Laryngoscope 123:1132–1135

    Article  PubMed  Google Scholar 

  24. Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130

    Article  CAS  PubMed  Google Scholar 

  25. van Essen M, Krenning EP, Kooij PP et al (2006) Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 47:1599–1606

    PubMed  Google Scholar 

  26. Bartolomei M, Bodei L, De Cicco C et al (2009) Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 36:1407–1416

    Article  CAS  PubMed  Google Scholar 

  27. Baldari S, Ferrau F, Alafaci C et al (2012) First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary 15(Suppl 1):S57–S60

    Article  PubMed  Google Scholar 

  28. Komor J, Reubi JC, Christ ER (2013) Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary. doi:10.1007/s11102-013-0494-0

  29. Siegel JA, Thomas SR, Stubbs JB et al (1999) MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40(2):37S–61S

    CAS  PubMed  Google Scholar 

  30. Pernicone PJ, Scheithauer BW, Sebo TJ et al (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79:804–812

    Article  CAS  PubMed  Google Scholar 

  31. Salehi F, Agur A, Scheithauer BW et al (2009) Ki-67 in pituitary neoplasms: a review–part I. Neurosurgery 65:429–437 discussion 437

    Article  PubMed  Google Scholar 

  32. Janssen MH, Ollers MC, van Stiphout RG et al (2012) PET-based treatment response evaluation in rectal cancer: prediction and validation. Int J Radiat Oncol Biol Phys 82:871–876

    Article  PubMed  Google Scholar 

  33. van Elmpt W, Ollers M, Dingemans AM et al (2012) Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J Nucl Med 53:1514–1520

    Article  PubMed  Google Scholar 

  34. Haug AR, Auernhammer CJ, Wangler B et al (2010) 68 Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 51:1349–1356

    Article  CAS  PubMed  Google Scholar 

  35. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754–2762

    Article  CAS  PubMed  Google Scholar 

  36. Hanscheid H, Sweeney RA, Flentje M et al (2012) PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging 39:1284–1288

    Article  PubMed  Google Scholar 

  37. Cremonesi M, Botta F, Di Dia A et al (2010) Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging 54:37–51

    CAS  PubMed  Google Scholar 

  38. Hindorf C, Chittenden S, Causer L et al (2007) Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors. Cancer Biother Radiopharm 22:130–135

    Article  CAS  PubMed  Google Scholar 

  39. Kaltsas GA, Papadogias D, Makras P et al (2005) Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 12:683–699

    Article  CAS  PubMed  Google Scholar 

  40. Villard L, Romer A, Marincek N et al (2012) Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 30:1100–1106

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. University College London Hospitals NHS Foundation Trust, 235 Euston Road, London, NW1 2BU, UK

    Jillian Maclean, Matthew Aldridge, Jamshed Bomanji, Susan Short & Naomi Fersht

  2. Leeds Institute of Cancer and Pathology, St James University Hospital, Beckett St, Leeds, LS9 7TF, UK

    Susan Short

Authors
  1. Jillian Maclean
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Aldridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jamshed Bomanji
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susan Short
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naomi Fersht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jillian Maclean.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maclean, J., Aldridge, M., Bomanji, J. et al. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation. Pituitary 17, 530–538 (2014). https://doi.org/10.1007/s11102-013-0540-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-013-0540-y

Keywords

Search

Navigation